Show simple item record

dc.contributor.authorLappalainen, Marika
dc.contributor.authorJokkala, Jenna
dc.contributor.authorJuutilainen, Auni
dc.contributor.authorHämäläinen, Sari
dc.contributor.authorKoivula, Irma
dc.contributor.authorJantunen, Esa
dc.contributor.authorHanhineva, Kati
dc.contributor.authorPulkki, Kari
dc.date.accessioned2018-05-07T08:05:49Z
dc.date.available2018-05-07T08:05:49Z
dc.date.issued2018
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6582
dc.description.abstractBackground. Novel potential small molecular biomarkers for sepsis were analyzed with nontargeted metabolite profiling to find biomarkers for febrile neutropenia after intensive chemotherapy for hematological malignancies. Methods. Altogether, 85 patients were included into this prospective study at the start of febrile neutropenia after intensive chemotherapy for acute myeloid leukemia or after autologous stem cell transplantation. The plasma samples for the nontargeted metabolite profiling analysis by liquid chromatography-mass spectrometry were taken when fever rose over 38° and on the next morning. Results. Altogether, 90 differential molecular features were shown to explain the differences between patients with complicated (bacteremia, severe sepsis, or fatal outcome) and noncomplicated courses of febrile neutropenia. The most differential compounds were an androgen hormone, citrulline, and phosphatidylethanolamine PE(18:0/20:4). The clinical relevance of the findings was evaluated by comparing them with conventional biomarkers like C-reactive protein and procalcitonin. Conclusion. These results hold promise to find out novel biomarkers for febrile neutropenia, including citrulline. Furthermore, androgen metabolism merits further studies.
dc.language.isoEN
dc.publisherHindawi Limited
dc.relation.ispartofseriesDISEASE MARKERS
dc.relation.urihttp://dx.doi.org/10.1155/2018/6964529
dc.rightsCC BY http://creativecommons.org/licenses/by/4.0/
dc.titleNovel Biomarker Candidates for Febrile Neutropenia in Hematological Patients Using Nontargeted Metabolomics
dc.description.versionpublished version
dc.contributor.departmentSchool of Medicine / Clinical Nutrition
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id54221906en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© Authors
dc.relation.doi10.1155/2018/6964529
dc.description.reviewstatuspeerReviewed
dc.format.pagerange6964529
dc.relation.issn0278-0240
dc.relation.volume2018
dc.type.okmA1
uef.solecris.openaccessOpen access -julkaisukanavassa ilmestynyt julkaisu


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record